Climb Bio (CLYM) Enterprise Value (2020 - 2026)

Climb Bio has reported Enterprise Value for 7 years, with the latest figure at -$109.6 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 11.73% year-over-year to -$109.6 million; the trailing twelve-month figure through Mar 2026 stood at -$109.6 million (down 11.73% YoY), and the FY2025 full-year result was -$101.1 million, up 33.02% from the prior year.
• Enterprise Value for Q1 2026 stood at -$109.6 million, down from -$101.1 million in the prior quarter.
• The five-year high for Enterprise Value was -$84.7 million in Q2 2025, with the low at -$261.7 million in Q3 2024.
• Historically, Enterprise Value has averaged -$153.5 million across 5 years, with a median of -$150.9 million in 2024.
• Annual changes were most pronounced in 2024 — Enterprise Value slumped 143.6% — and 2025, when it jumped 66.79%.
• Climb Bio's Enterprise Value stood at -$187.4 million in 2022, then jumped by 43.02% to -$106.8 million in 2023, then tumbled by 41.31% to -$150.9 million in 2024, then surged by 33.02% to -$101.1 million in 2025, then slipped by 8.39% to -$109.6 million in 2026.
• The last three Enterprise Value figures came in at -$109.6 million (Q1 2026), -$101.1 million (Q4 2025), and -$86.9 million (Q3 2025), per Business Quant data.